Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 6/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15074663 | 0.82 | ALDH1A1 (0.40) | KDM4ETDP1FAAHROCK1EPHX2 | |
| SCHEMBL4657505 | 0.77 | KMT2A (0.41) | KDM4ELMNARECQLALDH1A1NPC1 | |
| SCHEMBL13664090 | 0.77 | FGFR1 (0.38) | KDM4ETDP1ROCK1EPHX2ALDH1A1 | |
| SCHEMBL19026668 | 0.77 | MLYCD (0.39) | KDM4ETDP1ROCK1EPHX2ALDH1A1 | |
| SCHEMBL19563752 | 0.75 | IDO1 (0.60) | KDM4ETDP1FAAHROCK1LMNA | |
| Carbamic Acid SCHEMBL3227372 | 0.75 | KDM4E (0.57) | KDM4ETDP1EPHX2LMNARECQL | |
| SCHEMBL3178351 | 0.74 | ROCK1 (0.35) | KDM4ETDP1FAAHROCK1ALDH1A1 | |
| SCHEMBL11289967 | 0.73 | MLYCD (0.53) | KDM4ETDP1FAAHLMNAALDH1A1 | |
| SCHEMBL3170188 | 0.73 | CSNK2A2 (0.37) | KDM4ETDP1ROCK1ALDH1A1 | |
| SCHEMBL17324778 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053982-A1 | ETHER BENZYLIDENE PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053950-A1 | 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER, INC. | 2011-03-03 | — | — | US | disclosed |
| WO-2009127944-A1 | ETHER BENZYLIDENE PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| CN-1117738-C | Endothelin antagonists: N-[[2'-[[4,5-dimethyl-3-isoxazolyl) amino] sulfonyl]-4-(2-oxazolyl) [1,1'-biphenyl]-2-yl] methyl] | BRISTOL MYERS SQUIBB CO (US) | 2003-08-13 | — | — | CN | disclosed |
| CN-1244862-A | Endothelin antagonists N- [ [2' - [ [ (4, 5-dimethyl-3-isoxazolyl) amino ] sulfonyl ] -4- (2-oxazolyl) [1,1' biphenyl ] -2-yl ] methyl ] -N, 3, 3-trimethylbutanamide and N- (4, 5-dimethyl-3-isoxazolyl) -2 ' - [3, 3-dimethyl-2-oxo-1-pyrrolidinyl) methyl ] -4 ' -2-oxazolyl) [1,1' -biphenyl ] -2-sulfonamide and salts thereof | BRISTOL MYERS SQUIBB CO (US) | 2000-02-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053982-A1 | ETHER BENZYLIDENE PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | FAAH, FAAH2, CNR2 | KDM4E 542/4885TDP1 4125/4885FAAH 1/4885 |
| US-20110053950-A1 | 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | FAAH, FAAH2, CNR2 | KDM4E 626/4885TDP1 3887/4885FAAH 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.